PMID- 37103015
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231102
IS  - 2308-3425 (Electronic)
IS  - 2308-3425 (Linking)
VI  - 10
IP  - 4
DP  - 2023 Mar 23
TI  - Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 
      Diabetes Mellitus Patients with Chronic Heart Failure.
LID - 10.3390/jcdd10040136 [doi]
LID - 136
AB  - The aim of this study was to determine the discriminative value of irisin for 
      acutely decompensated heart failure (ADHF) in type 2 diabetes mellitus (T2DM) 
      patients with chronic HF. We included 480 T2DM patients with any phenotype of HF 
      and followed them for 52 weeks. Hemodynamic performances and the serum levels of 
      biomarkers were detected at the study entry. The primary clinical end-point was 
      ADHF that led to urgent hospitalization. We found that the serum levels of 
      N-terminal natriuretic pro-peptide (NT-proBNP) were higher (1719 [980-2457] 
      pmol/mL vs. 1057 [570-2607] pmol/mL, respectively) and the levels of irisin were 
      lower (4.96 [3.14-6.85] ng/mL vs. 7.95 [5.73-9.16] ng/mL) in ADHF patients than 
      in those without ADHF. The ROC curve analysis showed that the estimated cut-off 
      point for serum irisin levels (ADHF versus non-ADHF) was 7.85 ng/mL (area under 
      curve [AUC] = 0.869 (95% CI = 0.800-0.937), sensitivity = 82.7%, specificity = 
      73.5%; p = 0.0001). The multivariate logistic regression yielded that the serum 
      levels of irisin < 7.85 ng/mL (OR = 1.20; p = 0.001) and NT-proBNP > 1215 pmol/mL 
      (OR = 1.18; p = 0.001) retained the predictors for ADHF. Kaplan-Meier plots 
      showed a significant difference of clinical end-point accumulations in patients 
      with HF depending on irisin levels (<7.85 ng/mL versus >/=7.85 ng/mL). In 
      conclusion, we established that decreased levels of irisin were associated with 
      ADHF presentation in chronic HF patients with T2DM independently from NT-proBNP.
FAU - Berezin, Alexander A
AU  - Berezin AA
AD  - Department of Internal Medicine, Zaporozhye Medical Academy of Postgraduate 
      Education, 69096 Zaporozhye, Ukraine.
FAU - Obradovic, Anica Babic
AU  - Obradovic AB
AUID- ORCID: 0000-0002-1399-6682
AD  - Medical Practice for General Medicine, 22111 Hamburg, Germany.
FAU - Fushtey, Ivan M
AU  - Fushtey IM
AD  - Department of Internal Medicine, Zaporozhye Medical Academy of Postgraduate 
      Education, 69096 Zaporozhye, Ukraine.
FAU - Berezina, Tetiana A
AU  - Berezina TA
AUID- ORCID: 0000-0001-8109-3429
AD  - Vita Center, Department of Internal Medicine and Nephrology, 69000 Zaporozhye, 
      Ukraine.
FAU - Lichtenauer, Michael
AU  - Lichtenauer M
AD  - Division of Cardiology, Department of Internal Medicine II, Paracelsus Medical 
      University, 5020 Salzburg, Austria.
FAU - Berezin, Alexander E
AU  - Berezin AE
AUID- ORCID: 0000-0002-0446-3999
AD  - Division of Cardiology, Department of Internal Medicine II, Paracelsus Medical 
      University, 5020 Salzburg, Austria.
AD  - Department of Internal Medicine, Zaporozhye State Medical University, 69035 
      Zaporozhye, Ukraine.
LA  - eng
PT  - Journal Article
DEP - 20230323
PL  - Switzerland
TA  - J Cardiovasc Dev Dis
JT  - Journal of cardiovascular development and disease
JID - 101651414
PMC - PMC10144964
OTO - NOTNLM
OT  - acutely decompensated heart failure
OT  - cardiac remodeling
OT  - chronic heart failure
OT  - irisin
OT  - natriuretic peptides
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/27 12:42
MHDA- 2023/04/27 12:43
PMCR- 2023/03/23
CRDT- 2023/04/27 10:33
PHST- 2023/02/16 00:00 [received]
PHST- 2023/03/20 00:00 [revised]
PHST- 2023/03/21 00:00 [accepted]
PHST- 2023/04/27 12:43 [medline]
PHST- 2023/04/27 12:42 [pubmed]
PHST- 2023/04/27 10:33 [entrez]
PHST- 2023/03/23 00:00 [pmc-release]
AID - jcdd10040136 [pii]
AID - jcdd-10-00136 [pii]
AID - 10.3390/jcdd10040136 [doi]
PST - epublish
SO  - J Cardiovasc Dev Dis. 2023 Mar 23;10(4):136. doi: 10.3390/jcdd10040136.